
Provention Bio PRVB
Annual report 2022
added 03-29-2023
Provention Bio DSO Ratio 2011-2026 | PRVB
Annual DSO Ratio Provention Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.2 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 | 19.2 | 19.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Verastem
VSTM
|
38.5 | $ 5.04 | -4.73 % | $ 349 M | ||
|
Voyager Therapeutics
VYGR
|
14.8 | $ 3.96 | -4.12 % | $ 232 M | ||
|
VistaGen Therapeutics
VTGN
|
28.9 | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
60.7 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
11.5 | $ 6.37 | 2.66 % | $ 1.07 B | ||
|
Xenetic Biosciences
XBIO
|
365 | $ 2.72 | -2.86 % | $ 4.63 M | ||
|
XBiotech
XBIT
|
40.8 | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
72.6 | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
57.2 | $ 5.4 | -3.05 % | $ 866 M | ||
|
X4 Pharmaceuticals
XFOR
|
46.1 | $ 4.04 | -6.26 % | $ 171 M | ||
|
Xencor
XNCR
|
131 | $ 11.42 | -7.23 % | $ 848 M | ||
|
XOMA Corporation
XOMA
|
23.6 | $ 30.17 | -1.18 % | $ 364 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
22nd Century Group
XXII
|
54.9 | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Zai Lab Limited
ZLAB
|
75.9 | $ 18.0 | 2.8 % | $ 19.7 B |